MediWound Ltd. (MDWD) director discloses shares, RSUs and options stake
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
MediWound Ltd. director David Morton Fox filed an initial statement of beneficial ownership, outlining his equity stake in the company. He directly holds ordinary shares and additional ordinary shares underlying restricted stock units that were granted on March 4, 2026 and vest 100% on the one-year anniversary of the grant date.
Fox also reports a series of equity incentives. These include Series A warrants$13.4750 per share, expiring on November 28, 2026. He holds multiple stock option grants, such as options over 14,285 ordinary shares at $12.2500 per share expiring on June 29, 2030, and other tranches with exercise prices between $11.8850 and $37.5200 expiring from 2031 through 2036. This filing records existing holdings and does not show new market transactions.
Positive
- None.
Negative
- None.
Insider Trade Summary
10 transactions reported
Mixed
10 txns
Insider
Fox David Morton
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Series A Warrants | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Ordinary shares | -- | -- | -- |
| holding | Ordinary shares | -- | -- | -- |
Holdings After Transaction:
Series A Warrants — 6,534 shares (Direct);
Stock Option (right to buy ordinary shares) — 14,285 shares (Direct);
Ordinary shares — 18,746 shares (Direct)
Footnotes (1)
- The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date. The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date.
FAQ
What does the MediWound Ltd. (MDWD) Form 3 filing show for director David Morton Fox?
The Form 3 shows director David Morton Fox’s initial equity holdings in MediWound. It lists his direct ordinary share position, restricted stock units granted on March 4, 2026, and multiple stock option and warrant positions over ordinary shares with various exercise prices and expirations.
What are the main exercise prices and expirations of David Morton Fox’s MediWound (MDWD) derivative awards?
The filing shows a Series A warrant exercisable at $13.4750 expiring November 28, 2026. Stock options have exercise prices between $11.8850 and $37.5200, with expiration dates ranging from June 29, 2030 through March 4, 2036, providing long-dated exposure to MediWound shares.
Does the MediWound (MDWD) Form 3 for David Morton Fox report any stock purchases or sales?
The Form 3 does not report stock purchases or sales. It functions as an initial ownership snapshot, listing Fox’s existing ordinary share holdings, restricted stock units, and outstanding Series A warrants and stock options without indicating new market transactions in MediWound securities.
How are restricted stock units described in David Morton Fox’s MediWound (MDWD) Form 3?
The filing notes that certain ordinary shares reported consist of shares underlying restricted stock units granted on March 4, 2026. These RSUs are structured to vest 100% on the one-year anniversary of the grant date, reflecting time-based vesting rather than immediate share ownership.
What does MediWound (MDWD) investors learn from the derivativeSummary in David Morton Fox’s Form 3?
The derivativeSummary shows Fox’s remaining unexercised Series A warrants and stock options over MediWound ordinary shares. It details each award’s exercise price, expiration date, and underlying share count, clarifying the scale and timing of his potential future share acquisitions through equity incentives.